Diacylglycerol-induced improvement of whole-body insulin sensitivity in type 2 diabetes mellitus: a long-term randomized, double-blind controlled study.
Diacylglycerol oil has been shown to lower postprandial and fasting serum triacylglycerol levels and reduce body fat. The aim of this study was to investigate the effect of diacylglycerol oil on risk factors of type 2 diabetes mellitus (DM) and cardiovascular disease in type 2 DM patients. This was a double-blind controlled parallel study with 127 type 2 DM patients (aged 40-65) recruited in Hangzhou, China. All subjects consumed triacylglycerol oil in the lead-in period (14 days), then they were randomly divided into two groups and consumed diacylglycerol or triacylglycerol oil with a similar fatty acid composition (25 g/day) for 120 days. Blood samples were collected on days 0, 60 and 120 and risk factors of type 2 DM and cardiovascular disease and biochemical parameters were measured by standard methods. There were a total of 112 subjects who completed the study. Diet intake did not differ significantly between groups. Body weight, BMI, waist circumference, HOMA-IR, serum insulin and leptin levels were significantly reduced from baseline in the diacylglycerol oil group but not in the triacylglycerol oil group. Serum glucose was also significantly improved in patients with higher glucose levels at baseline (>7.00 mmol/L) in the diacylglycerol oil group. Parameters of liver and kidney functions and essential fatty acids in serum phospholipids did not differ between groups. Diacylglycerol oil consumption improved biomarkers and anthropometric parameters of type 2 DM compared with triacylglycerol oil. No adverse reactions were observed with diacylglycerol oil consumption for type 2 DM patients. Diacylglycerol oil has an equivalent bioavailability as triacylglycerol oil in relation to providing essential fatty acids.